|
|
|
| Clinical Effect of Combining Dapagliflozin and Qili Qiangxin Capsule on Conventional Therapy for Chronic Heart Failure with Heart-Kidney Yang Deficiency Syndrome |
| CAI Minghui1, ZHENG Ting1, WANG Yan2, XU Yuping1 |
1. Pengpu Xincun Community Health Service Center, Shanghai 200435;
2. Shibei Hospital of Jing'an District, Shanghai 200435 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical effect of combining dapagliflozin and Qili Qiangxin Capsule on conventional therapy for chronic heart failure (CHF) with heart-kidney yang deficiency syndrome. 【Methods】 Clinical data of 120 patients with CHF and heart-kidney yang deficiency syndrome admitted to Shibei Hospital of Jing'an District from January 2022 to December 2024 were retrospectively analyzed. Patients were divided into a control group (receiving oral dapagliflozin based on conventional therapy, n=60) and an observation group (receiving oral Qili Qiangxin Capsule in addition to the control group regimen, n=60) according to different treatment methods. Cardiac function indicators [left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac index (CI)], traditional Chinese medicine (TCM) syndrome scores, and adverse reactions were compared between the two groups. 【Results】 After treatment, LVEF, SV, and CI in both groups were higher than before treatment, and these indicators in the observation group were higher than those in the control group, with statistically significant differences (P<0.05). After treatment, the primary syndrome scores, secondary syndrome scores, and total scores in both groups were lower than before treatment, and the scores in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). The total incidence of adverse reactions was 8.33% (5/60) in the observation group and 6.67% (4/60) in the control group, with no statistically significant difference between the two groups (χ2=0.12,P=0.729). 【Conclusion】 Combining dapagliflozin with Qili Qiangxin Capsule in addition to conventional therapy can significantly improve cardiac function and alleviate clinical symptoms in patients with CHF and heart-kidney yang deficiency syndrome, with a favorable safety profile.
|
|
Received: 27 November 2025
|
|
|
|
|
|
[1] 王欣,张媛,刘佳,等. 中性粒细胞百分比/血红蛋白比值对重症慢性心力衰竭患者1年全因死亡的影响[J].中国心血管杂志,2024,29(2):131-136.
[2] 何文凤,薛成,郑健康,等. 参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭对hs-CRP、BNP、AngⅡ及心功能的影响[J].中华中医药学刊,2024,42(6):95-98.
[3] 庞延,毛美玲,卢健棋,等. 强心汤对慢性心力衰竭大鼠心肌线粒体稳态和能量代谢的影响[J].中国药房,2024,35(15):1831-1836.
[4] 徐坤,张晓敏,党静,等. 沙库巴曲缬沙坦联合达格列净治疗老年慢性心力衰竭合并2型糖尿病患者的临床研究[J].中国临床药理学杂志,2024,40(17):2464-2468.
[5] 赵志坤,王磊,张津津,等. 芪苈强心胶囊联合沙库巴曲缬沙坦钠对老年慢性心力衰竭患者血清Gal-3、Copeptin水平及TLR4/NF-κB信号通路的影响[J].现代生物医学进展,2022,22(3):486-490.
[6] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 心脏再同步治疗慢性心力衰竭的中国专家共识(2021年修订版)[J].中华心律失常学杂志,2021,25(6):465-478.
[7] 李霁敏,程丽荣,黄光明,等. 芪参茯苓膏和芪苈强心胶囊联合西药治疗慢性心力衰竭的疗效及对血清BNP、CRP、D-二聚体水平的影响[J].中西医结合心脑血管病杂志,2024,22(12):2203-2206.
[8] 王进,左莉莉,高琛琛. 芪苈强心胶囊对慢性心力衰竭患者肠道菌群、血浆TNF-α、IL-Iβ、H-FABP和TMAO水平及心功能的影响[J].分子诊断与治疗杂志,2024,16(12):2329-2332.
[9] 葛腾,李舒钰,宁博,等. 芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭有效性及安全性的Meta分析[J].中西医结合心脑血管病杂志,2023,21(14):2531-2542.
[10] 刘颖,张军,毕菲菲,等. 参附芪苈汤加减联合恩格列净治疗2型糖尿病合并慢性心力衰竭急性加重患者的临床效果及对心功能、血管内皮功能的影响[J].中国医院用药评价与分析,2023,23(8):953-958.
[11] 赵达,赵振宇,叶嘉豪,等. 基于网络药理学和分子对接技术探讨芪苈强心胶囊治疗慢性心力衰竭的作用机制[J].湖南中医药大学学报,2022,42(6):950-957.
[12] 安家瑶,王雪琪. 左西孟旦联合芪苈强心胶囊对老年慢性心力衰竭患者疗效及心室重构指标的影响观察[J].贵州医药,2024,48(3):385-387.
[13] 胡广茂,陈艳俏,孙久林,等. 参附芪苈汤加减治疗慢性心力衰竭急性加重期的疗效及对病人血液流变学的影响[J].中西医结合心脑血管病杂志,2022,20(8):1448-1453.
[14] 骆睿翔,张晨,吴旸,等. 基于网络药理学与分子对接探讨芪苈强心胶囊治疗慢性心力衰竭的作用机制[J].中西医结合心脑血管病杂志,2022,20(12):2113-2124.
[15] 李世阁,叶章正,林英娜,等. 芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭临床疗效及对N末端脑利钠肽前体、超敏C反应蛋白和炎症因子的影响[J].河北中医,2022,44(7):1119-1122. |
|
|
|
2026, Vol. 43 
